Burning Rock Biotech Targets Cancer Via Advanced Diagnostics

Burning Rock Biotech Limited is at the forefront of developing and commercializing advanced cancer therapy selection tests. Operating in both China and the United States, the company focuses on delivering precise diagnostic solutions across its central laboratory, in-hospital, and pharma R&D services.

Their comprehensive portfolio includes next-generation sequencing tests for numerous cancer types, employing both tissue and liquid biopsy methods. Key products like OncoScreen Plus and OncoCompass Plus aim to identify treatment pathways and predict patient prognosis, revolutionizing cancer care.

Further enhancing its research capabilities, Burning Rock Biotech has forged significant development and commercialization agreements with industry leaders. Collaborations with entities such as Myriad Genetics, AstraZeneca, and Johnson & Johnson underscore its commitment to advancing global cancer diagnostics and treatment.